Mediar Therapeutics is pioneering a new approach to fibrosis treatment that aims to halt the disease at a different source – the myofibroblast, the key pathogenic cell in fibrosis that drives scarring, disease progression, and ultimately organ failure.
Mediar was founded based on a deep understanding of the complex science underlying fibrosis progression. By combining novel targets with reliable, easily detectable blood biomarkers and familiar modalities, Mediar’s goal is to bring forward novel anti-fibrotic therapies that potentially have a precision medicine approach.
For more information, contact info@mediartx.com
Company Details
- Employees
- 52
- Founded
- -
- Address
- 20 Overland St,
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- mediartx.com
- HQ
- Boston, Massachusetts
Mediar Therapeutics Questions
Mediar Therapeutics's website is mediartx.com
Mediar Therapeutics's LinkedIn profile is https://www.linkedin.com/company/mediar-therapeutics
Mediar Therapeutics has
52 employees.
View email and phone details for 52
employees at Mediar Therapeutics.
Mediar Therapeutics's industry is
Biotechnology Research
Mediar Therapeutics's top competitors are
Vor Bio,
Zenon Biotech,
Agios Pharmaceuticals,
Eledon Pharmaceuticals, Inc.,
Visterra Inc.,
Seismic Therapeutic,
Moma Therapeutics,
Tessera Therapeutics,
Apogee Therapeutics,
Remix Therapeutics.
Mediar Therapeutics's categories are Biotechnology Research
Mediar Therapeutics's founding year is 2019
